title: Asymmetric hydrogenation of a 4,4-diaryl-3-butenoate; a novel approach to sertraline.
abstract: The asymmetric hydrogenation of a selectively crystallised (E)-4,4-diaryl-3-butenoate with a rhodium-PhanePhos catalyst is described, providing an intermediate to the antidepressant sertraline.
authors.affiliation: Dowpharma, Chirotech Technology Limited, Dow Chemical Company, Cambridge Science Park, Unit 321, Milton Road, Cambridge, UK CB4 0WG. lboulton@dow.com
authors.forename: Lee T
authors.initials: LT
authors.lastname: Boulton
authors.forename: Ian C
authors.initials: IC
authors.lastname: Lennon
authors.forename: Raymond
authors.initials: R
authors.lastname: McCague
mesh_terms: D000928:Antidepressive Agents / Q000138:chemical synthesis* / Q000737:chemistry; D002087:Butyrates / Q000737:chemistry*; D002384:Catalysis; D006865:Hydrogenation; D015394:Molecular Structure; D012238:Rhodium / Q000737:chemistry; D020280:Sertraline / Q000138:chemical synthesis* / Q000737:chemistry
chemical_list: D000928:Antidepressive Agents; D002087:Butyrates; D012238:Rhodium; D020280:Sertraline